- Global Cefaclor Industry Report 2016
- The report, 'Global Cefaclor Industry Report 2016' provides detailed market and segment level data on the Global and Chinese consumption of Cefaclor.
- Flamel Technologies SA: Flamel Technologies Reports Fourth Quarter and Full
- The Company expects newly acquired FSC products, AcipHex® Sprinkle™, Karbinal™ ER, Cefaclor for Oral Suspension and Flexichamber ™, to generate revenues in the range of $10 - $15 million in 2016.
- Flamel Technologies to Report Fourth Quarter and Full Year 2015 Results
- In February 2016, Flamel acquired FSC Pediatrics, a Charlotte, North Carolina-based company that markets three pediatric pharmaceutical products Cefaclor for oral suspension, indicated for infection, Karbinal™ ER, indicated for allergic rhinitis and ...
- Despite words to the contrary, Flamel's $20M acquisition is a clear drug
- In addition, Flamel takes over the U.S.
- FSC Laboratories, Inc. to Market Cefaclor for Oral Suspension in the U.S.
- CHARLOTTE, N.C.--(BUSINESS WIRE)--FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Yung Shin Pharm.
Cefaclor is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Cefaclor books and related discussion.
Suggested News Resources
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.